Addition of Dexmedetomidine to the Anesthesia Regimen Attenuates Pain and Improves Early Recovery After Esophageal Endoscopic Submucosal Dissection: A Randomized Controlled Trial

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Oct 16

PMID 39411154

Authors

Xin Luo

Hai-Jun Hou

Pei-Shan Chen

Xin-Lu Chang

Yang Li

Li-Xin An

Fu-Kun Liu

Fu-Shan Xue

Affiliations

Soon will be listed here.

Abstract

Objective: Postoperative pain is a common yet often underestimated complication following esophageal endoscopic submucosal dissection (ESD), with limited strategies for effective management. This prospective, double-blind, randomized controlled trial assessed the effects of adding dexmedetomidine (DEX) to the anesthesia regimen on postoperative pain and early recovery in patients undergoing esophageal ESD.

Methods: In total, 60 patients scheduled for elective esophageal ESD under general anesthesia were randomly assigned to the DEX or control group. The DEX group received an intravenous loading dose of DEX at 1 μg/kg for 10 min, followed by a continuous intravenous infusion of 0.6 µg/kg/h, which was stopped 30 min before the end of the procedure. The control group received normal saline as a placebo. The study's primary outcome was the incidence of moderate-to-severe postoperative pain. Secondary outcomes included postoperative pain scores, hemodynamic parameters, the occurrence of postoperative nausea and vomiting (PONV), patient satisfaction, and lengths of stay in the post-anesthesia care unit (PACU) and hospital.

Results: The incidence of moderate-to-severe postoperative pain in the DEX group was significantly lower than that in the control group (absolute difference: -33.4%; OR: 0.250; 95% CI: 0.085-0.731, = 0.01). Pain scores at 1 h postoperatively (0.5[2.0] 3.0[1.3], = 0.003) were significantly lower in the DEX group. Additionally, morphine dosage in the PACU (0[0] 1.0[2.0] = 0.004) was significantly reduced in the DEX group compared with the control group. In the DEX group, the incidence and severity of PONV were significantly decreased and the length of PACU stay was shorter than in the control group ( 0.01). However, the rates of intraoperative hypotension, tachycardia, and bradycardia were similar between the two groups. Patient satisfaction and length of hospital stay were also comparable.

Conclusion: Adding DEX to the anesthesia regimen for esophageal ESD significantly attenuates postoperative pain and improves early recovery outcomes.

References

Vijayan N, Talwar V, Dayal M . Comparative Evaluation of the Effects of Pregabalin, Dexmedetomidine, and Their Combination on the Hemodynamic Response and Anesthetic Requirements in Patients undergoing Laparoscopic Cholecystectomy: A Randomized Double-Blind Prospective Study. Anesth Essays Res. 2019; 13(3):515-521. PMC: 6775847. DOI: 10.4103/aer.AER_86_19. View

Li J, Kang G, Liu T, Liu Z, Guo T . Feasibility of Enhanced Recovery After Surgery Protocols Implemented Perioperatively in Endoscopic Submucosal Dissection for Early Gastric Cancer: A Single-Center Retrospective Study. J Laparoendosc Adv Surg Tech A. 2022; 33(1):74-80. DOI: 10.1089/lap.2022.0269. View

Kim J, Nam H, Choi C, Kang D, Kim H, Park S . Risk factors associated with difficult gastric endoscopic submucosal dissection: predicting difficult ESD. Surg Endosc. 2016; 31(4):1617-1626. DOI: 10.1007/s00464-016-5149-6. View

Schulz K, Altman D, Moher D . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c332. PMC: 2844940. DOI: 10.1136/bmj.c332. View

Iirola T, Vilo S, Aantaa R, Wendelin-Saarenhovi M, Neuvonen P, Scheinin M . Dexmedetomidine inhibits gastric emptying and oro-caecal transit in healthy volunteers. Br J Anaesth. 2011; 106(4):522-7. DOI: 10.1093/bja/aer004. View

Wan L, Shao L, Liu Y, Wang H, Xue F, Tian M . Dexmedetomidine reduces sevoflurane EC for supraglottic airway device insertion in spontaneously breathing morbidly obese patients. Ther Clin Risk Manag. 2019; 15:627-635. PMC: 6504637. DOI: 10.2147/TCRM.S199440. View

Lee S, Sung I, Kim J, Lee S, Park H, Shim C . Comparison of dexmedetomidine with on-demand midazolam versus midazolam alone for procedural sedation during endoscopic submucosal dissection of gastric tumor. J Dig Dis. 2015; 16(7):377-84. DOI: 10.1111/1751-2980.12254. View

Yoshio T, Ishiyama A, Tsuchida T, Yoshimizu S, Horiuchi Y, Omae M . Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma. Esophagus. 2019; 16(3):285-291. DOI: 10.1007/s10388-019-00666-z. View

Ogasawara N, Yoshimine T, Noda H, Kondo Y, Izawa S, Shinmura T . Clinical risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal tumors in Japanese patients. Eur J Gastroenterol Hepatol. 2016; 28(12):1407-1414. DOI: 10.1097/MEG.0000000000000723. View

10.

Nonaka T, Inamori M, Miyashita T, Harada S, Inoh Y, Kanoshima K . Feasibility of deep sedation with a combination of propofol and dexmedetomidine hydrochloride for esophageal endoscopic submucosal dissection. Dig Endosc. 2015; 28(2):145-51. DOI: 10.1111/den.12559. View

11.

Ma D, Youn Y, Jung D, Park J, Kim J, Park H . Risk factors of electrocoagulation syndrome after esophageal endoscopic submucosal dissection. World J Gastroenterol. 2018; 24(10):1144-1151. PMC: 5850133. DOI: 10.3748/wjg.v24.i10.1144. View

12.

Zhao D, Liu Y, Wang L, Xu G, Lv Y, Ling T . Factors influencing development of non-cardiac chest pain after endoscopic submucosal dissection for esophageal neoplasms: a retrospective case-control study of 309 patients from a single center. Dis Esophagus. 2021; 34(10). DOI: 10.1093/dote/doaa126. View

13.

Nishizawa T, Yahagi N . Endoscopic mucosal resection and endoscopic submucosal dissection: technique and new directions. Curr Opin Gastroenterol. 2017; 33(5):315-319. DOI: 10.1097/MOG.0000000000000388. View

14.

Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M . Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005; 3(7 Suppl 1):S67-70. DOI: 10.1016/s1542-3565(05)00291-0. View

15.

Kim S, Kim J, Lee J, Song B, Koo B . Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth. 2013; 111(2):222-8. DOI: 10.1093/bja/aet056. View

16.

Liao Y, Min J, Wu Z, Hu Z . Comparison of the effects of remimazolam and dexmedetomidine on early postoperative cognitive function in elderly patients with gastric cancer. Front Aging Neurosci. 2023; 15:1123089. PMC: 10277633. DOI: 10.3389/fnagi.2023.1123089. View

17.

Ramsay M, Luterman D . Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004; 101(3):787-90. DOI: 10.1097/00000542-200409000-00028. View

18.

Lin C, Williams B . Postoperative nausea and vomiting in ambulatory regional anesthesia. Int Anesthesiol Clin. 2011; 49(4):134-43. DOI: 10.1097/AIA.0b013e318216bf9c. View

19.

Zhou W, Zhang D, Tian S, Tan C, Ma R, Zhang J . Optimal Dose of Dexmedetomidine for Perioperative Blood Glucose Regulation in Non-Diabetic Patients Undergoing Gastrointestinal Malignant Tumor Resection: A Randomized Double-Blinded Controlled Trial. J Invest Surg. 2020; 34(8):869-874. DOI: 10.1080/08941939.2019.1706673. View

20.

Kaye A, Chernobylsky D, Thakur P, Siddaiah H, Kaye R, Eng L . Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain. Curr Pain Headache Rep. 2020; 24(5):21. PMC: 7223065. DOI: 10.1007/s11916-020-00853-z. View